CDK4 and neoplasm: Although the efficacy of combining HT and CDK4 and CDK6 inhibitor in patients with ESR1+/HER2− breast cancer, the promising benefit of CDK4 and CDK6 drug inhibitors in other neoplasms has not been extensively tested.